Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: A cross-sectional analysis of 311 patients

Lupus

Volumn 25, Issue 2, 2016, Pages 177-184

  Demir, S ^a   Artim Esen, B ^a   Sahinkaya Y ^a   Pehlivan, O ^a   Alpay Kanltez, N ^a   Omma, A ^a   Erer, B ^a   Kamall, S ^a   Gul A ^a   Aral, O ^a   Ocal L ^a   Inanc M ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

cardiovascular disease; Metabolic syndrome; systemic lupus erythematosus

Indexed keywords

HYDROXYCHLOROQUINE; PHOSPHOLIPID ANTIBODY; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL STUDY; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METABOLIC SYNDROME X; NEUROLOGIC DISEASE; PERICARDITIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINIC DAMAGE INDEX; THROMBOCYTOPENIA; CARDIOVASCULAR DISEASES; IMMUNOLOGY; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PATHOLOGY; PHENOTYPE; RISK FACTOR;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIRHEUMATIC AGENTS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PHENOTYPE; RISK FACTORS; THROMBOCYTOPENIA;

EID: 84954242846     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315603140     Document Type: Article

References (36)

1. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA,. The bimodal mortality in systemic lupus erythematosus. Am J Med 1976; 60: 221-225.
2. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary arterial atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407-2415.
3. Bruce IN,. 'Not only...but also': Factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 2005; 44: 1492-1502.
4. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study. Am J Epidemiol 1997; 145: 408-415.
5. Bruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G,. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum 2003; 48: 3159-3167.
6. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, Berger RD,. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-2337.
7. Svenungsson E, Jensen-Urstad K, Heimbürger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887-1893.
8. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C,. Definition of metabolic syndrome: Report of the National Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
9. Kip KE, Marraquin OC, Kelley DE, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: A report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation 2004; 109: 706-713.
10. Magadmi ME, Ahmad Y, Turkie W, et al. Hyperinsulinemia, insulin resistance and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 2006; 33: 50-56.
11. Chung CP, Avalos I, Oeser A, et al. High prevalence of metabolic syndrome in patients with systemic lupus erythematosus: Association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66: 208-214.
12. Grundy SM,. Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093-1100.
13. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH,. The metabolic syndrome and insulin resistance: Relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis 2005; 181: 101-108.
14. Laaksonen DE, Niskanen L, Nyyssönen K, et al. C-reactive protein and the development of metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004; 47: 1403-1410.
15. Grundy SM,. Metabolic syndrome pandemic. Artheroscler Thromb Vasc Biol 2008; 28: 629-636.
16. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
17. Gladman DD, Ibañez D, Urowitz MB,. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-291.
18. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
19. Onat A, Yüksel M, Köroʇlu B, et al. Turkish Adult Risk Factor Study survey 2012: Overall and coronary mortality and trends in the prevalence of metabolic syndrome [article in Turkish]. Turk Kardiyol Dern Ars 2013; 41: 373-378.
20. Bultink IE, Turkstra F, Diamant M, Dijkmans BAC, Voskuyl AE,. Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus. Clin Exp Rheumatol 2008; 26: 32-38.
21. Sabio JM, Zamora-Pasadas M, Jiménez-Jáimez J, et al. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 2008; 17: 849-859.
22. Parker B, Bruce I,. SLE and metabolic syndrome. Lupus 2013; 22: 1259-1266.
23. Telles R, Lanna C, Ferreira G, Ribeiro A,. Metabolic syndrome in patients with systemic lupus erythematosus: Association with traditional risk factors for coronary heart disease and lupus characteristics. Lupus 2010; 19: 803-809.
24. Liu SY, Han LS, Guo JY, et al. Metabolic syndrome in Chinese patients with systemic lupus erythematosus: No association with plasma cortisol level. Lupus 2013; 22: 519-526.
25. Bellomio V, Spindler A, Lucero E, et al. Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus 2009; 18: 1019-1025.
26. Negrón AM, Molina MJ, Mayor AM, Rodríguez VE, Vilá LM,. Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus 2008; 17: 348-354.
27. Parker B, Urowitz MB, Gladman DD, et al. Clinical associations of metabolic syndrome in systemic lupus erythematosus: Data from an international inception cohort. Ann Rheum Dis 2013; 72: 1308-1314.
28. Parker B, Ahmad Y, Shelmerdine J, et al. An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus 2011; 20: 1459-1465.
29. Parker B, Urowitz MB, Gladman DD, et al. Impact of early disease factors on metabolic syndrome in in systemic lupus erythematosus: Data from an international inception cohort. Ann Rheum Dis 2015; 74: 1530-1536.
30. Petri M, Ferman D, Goldman D,. Hypoglycemic effect of hydroxychloroquine in systemic lupus erythematosus. Arthritis Rheum 1994; 37 (Suppl): R24.
31. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA,. Cholesterol lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322-326.
32. Bevan AP, Krook A, Tikerpae J, Seabright PJ, Siddle K, Smith GD,. Chloroquine extends the lifetime of the activated insulin receptor complex in endosomes. J Biol Chem 1997; 272: 26833-26840.
33. Toloza SM, Uribe AG, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic US cohort. XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50: 3947-3957.
34. Petri M, Perez-Gutthann S, Spence D, Hochberg MC,. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-519.
35. Urowitz MB, Gladman D, Ibañez D, et al. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62: 881-887.
36. Urowitz MB, Ibañez D, Gladman DD,. Atherosclerotic vascular events in a single large lupus cohort: Prevalence and risk factors. J Rheumatol 2007; 34: 70-75.